Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults

Blood - Tập 129 - Trang 3322-3331 - 2017
Rebecca A. Gardner1,2,3, Olivia Finney1, Colleen Annesley1,2,3, Hannah Brakke1, Corinne Summers1,2, Kasey Leger1, Marie Bleakley2, Christopher Brown1, Stephanie Mgebroff1, Karen S. Kelly-Spratt1, Virginia Hoglund1, Catherine Lindgren1, Assaf P. Oron3, Daniel Li4, Stanley R. Riddell5,6, Julie R. Park1,2,3, Michael C. Jensen1,2,5
1Ben Towne Center for Childhood Cancer Research, Seattle Children's Research Institute, Seattle, WA
2Department of Pediatrics, University of Washington, Seattle, WA
3Center for Clinical and Translational Research, Seattle Children's Research Institute, Seattle, WA
4Clinical Statistics Group, Juno Therapeutics, Inc., Seattle, WA
5Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA
6Department of Medicine, University of Washington, Seattle, WA

Tóm tắt

Publisher's Note: There is an Inside Blood Commentary on this article in this issue.

Tài liệu tham khảo

Maude, 2014, Chimeric antigen receptor T cells for sustained remissions in leukemia, N Engl J Med, 371, 1507, 10.1056/NEJMoa1407222 Lee, 2015, T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial, Lancet, 385, 517, 10.1016/S0140-6736(14)61403-3 Turtle, 2016, CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients, J Clin Invest, 126, 2123, 10.1172/JCI85309 Turtle, 2016, Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells, Sci Transl Med, 8, 355ra116, 10.1126/scitranslmed.aaf8621 Porter, 2015, Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia, Sci Transl Med, 7, 303ra139, 10.1126/scitranslmed.aac5415 Brentjens, 2013, CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia, Sci Transl Med, 5, 177ra38, 10.1126/scitranslmed.3005930 Davila, 2014, Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia, Sci Transl Med, 6, 224ra25, 10.1126/scitranslmed.3008226 Singh, 2016, Early memory phenotypes drive T cell proliferation in patients with pediatric malignancies, Sci Transl Med, 8, 320ra3, 10.1126/scitranslmed.aad5222 Kawalekar, 2016, Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells [published correction appears in Immunity. 2016;44(3):712], Immunity, 44, 380, 10.1016/j.immuni.2016.01.021 Sommermeyer, 2016, Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo, Leukemia, 30, 492, 10.1038/leu.2015.247 Hudecek, 2015, The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity, Cancer Immunol Res, 3, 125, 10.1158/2326-6066.CIR-14-0127 Wang, 2011, A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells, Blood, 118, 1255, 10.1182/blood-2011-02-337360 Gattinoni, 2011, A human memory T cell subset with stem cell-like properties, Nat Med, 17, 1290, 10.1038/nm.2446 Yang, 2013, Modulating the differentiation status of ex vivo-cultured anti-tumor T cells using cytokine cocktails, Cancer Immunol Immunother, 62, 727, 10.1007/s00262-012-1378-2 Gardner, 2016, Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy, Blood, 127, 2406, 10.1182/blood-2015-08-665547 Kochenderfer, 2012, B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells, Blood, 119, 2709, 10.1182/blood-2011-10-384388 Savoldo, 2011, CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients, J Clin Invest, 121, 1822, 10.1172/JCI46110 Sotillo, 2015, Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy, Cancer Discov, 5, 1282, 10.1158/2159-8290.CD-15-1020 Haso, 2013, Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia, Blood, 121, 1165, 10.1182/blood-2012-06-438002